Dexcom appoints Dr. Euan Ashley to board; board size expanded to 11 in 2026

DEXCOM INC

Appointed Euan Ashley, M.D., to Board effective Oct 24, 2025; board size increased to 10 then to 11 effective Jan 1, 2026.
Ashley chairs Stanford Dept. of Medicine, co-founded 7 biotech firms, brings clinical and AI/digital health expertise.
Received initial RSU grant of $500k vesting over 3 years; eligible for annual director equity grant of $345k.
Appointed to Nominating and Governance Committee and Technology Committee; Kyle Malady steps down from Nominating but remains Tech chair.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.